logo-loader
viewRedx Pharma Plc

Redx Pharma project receives grant funding

The AIM-listed group is collaborating with the Medicines Discovery Catapult, a government body that helps accelerate the discovery of new treatments

Redx Pharma Plc -

Redx Pharma PLC (LON:REDX) said grant funding for its latest project provided “validation” of its scientific capabilities.

The AIM-listed group is collaborating with the Medicines Discovery Catapult, a government body that helps accelerate the discovery of new treatments.

The work will focus on potential new drugs for idiopathic pulmonary fibrosis (IPF), a life-threatening fibrotic lung condition.

The partnership has been awarded Biomedical Catalyst funding by Innovate UK, an arm’s length government operation that bankrolls research projects. No financial details were given.

Redx will provide expertise in the development of precision medicines, including its company's Porcupine and ROCK 2 inhibitors, which have been designed to tackle fibrosis and inflammation.

The MDC, meanwhile, will develop biomarker strategies, which measure the presence and severity of disease.

"We are excited to enter into this unique collaboration with Medicines Discovery Catapult and would like to thank Innovate UK for the validation of our teams' scientific capabilities with the Biomedical Catalyst funding award,” said  Dr Richard Armer, Redx’s chief scientific officer.

“This will accelerate preclinical assessment and ensure a robust clinical development plan is in place for our Porcupine and ROCK2 inhibitors for fibrosis."

Quick facts: Redx Pharma Plc

Price: 7 GBX

AIM:REDX
Market: AIM
Market Cap: £8.85 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Redx Pharma Plc named herein, including the promotion by the Company of Redx Pharma Plc in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Redx Pharma's chief scientific officer talks grant funding for its fibrosis...

Redx Pharma PLC's (LON:REDX) chief scientific officer Dr Richard Armer speaks to Proactive London's Andrew Scott after announcing they'd won grant funding for their latest project. They're collaborating with the Medicines Discovery Catapult, a government body that helps accelerate the...

3 weeks, 4 days ago

2 min read